No evidence supplement prevents AD cognitive decline
Souvenaid, widely touted as having potential for reducing cognitive decline in patients with Alzheimer’s Disease, does not appear to have any such impact, research has indicated.
Launched in Australia at last year’s Australian Pharmacy Professional (APP) conference, Souvenaid, is a dietary supplement marketed as a daily drink that provides a range of nutrients.
According to NPS Medicinewise, it is hypothesised that increasing the systemic concentration of nutrients required for the formation of phosphatidylcholine, a major constituent of synaptic membranes, will increase synapse formation and function and reduce cognitive decline in patients with AD.
However, analysis of three randomised controlled trials has “failed to show a significant effect of Souvenaid in decreasing the rate of cognitive decline or delaying AD progression.” Contact – Read more…